Megan V Caram
Clinical Associate Professor of Internal Medicine
Division of Hematology/Oncology
1500 E. Medical Center Drive
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Megan V Caram
Clinical Associate Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • Qualifications
    • Fellow
      VA Center for Clinical Management Research, Health Services Research and Development, 2016
    • Fellow
      University of Michigan Medical School, Division of Hematology/Oncology, 2013
    • Intern/Resident
      University of Michigan Medical School, Department of Internal Medicine, 2010
    • Mentor
      University of Michigan–Ann Arbor, Michigan Mentorship Academy
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Research Overview

    My research program has focused on minimizing harm to patients with different forms of cancer and on understanding the variability in the delivery of cancer care across the country. With a multidisciplinary team, I have investigated factors that influence unwarranted variation in the care of men with advanced prostate cancer, such as race, geography, insurance, provider, and cost. Understanding these factors will guide us in efforts to mitigate the impact of these non-clinical factors on the delivery of cancer care.

    Recent Publications See All Publications
    • Journal Article
      Unpacking overuse of androgen deprivation therapy for prostate cancer to inform de-implementation strategies.
      Skolarus TA, Hawley ST, Forman J, Sales AE, Sparks JB, Metreger T, Burns J, Caram MV, Radhakrishnan A, Dossett LA, Makarov DV, Leppert JT, Shelton JB, Stensland KD, Dunsmore J, Maclennan S, Saini S, Hollenbeck BK, Shahinian V, Wittmann DA, Deolankar V, Sriram S. Implement Sci Commun, 2024 Apr 9; 5 (1): 37 DOI:10.1186/s43058-024-00576-x
      PMID: 38594740
    • Journal Article
      Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
      Triner D, Daignault-Newton S, Singhal U, Sessine M, Dess RT, Caram MEV, Borza T, Ginsburg KB, Lane BR, Morgan TM, Michigan Urological Surgery Improvement Collaborative . Urol Oncol, 2024 Jul; 42 (7): 220.e1 - 220.e8. DOI:10.1016/j.urolonc.2024.03.015
      PMID: 38570271
    • Journal Article
      The 340B Program and oral specialty drugs for advanced prostate cancer.
      Faraj KS, Kaufman SR, Oerline M, Herrel LA, Maganty A, Caram MEV, Shahinian VB, Hollenbeck BK. Cancer, 2024 Jun 15; 130 (12): 2160 - 2168. DOI:10.1002/cncr.35262
      PMID: 38395607
    • Journal Article
      Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70.
      Chung DH, Caverly TC, Schipper MJ, Saini SD, Gulati R, Rose BS, Caram MV, Tsao PA, Stensland KD, Bryant A. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 5028 - 5028. DOI:10.1200/jco.2024.42.16_suppl.5028
    • Journal Article
      Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer
      Caram MEV, Kumbier K, Tsao PA, Burns J, Sparks JB, Stensland KD, Reichert ZR, Alumkal JJ, Hollenbeck BK, Shahinian V, Tsodikov A, Skolarus TA. Cancer Medicine, 2024 Jun 1; 13 (12): DOI:10.1002/cam4.7334
    • Journal Article
      Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
      Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J, Reichert ZR, Palmbos PL, Caram MEV, Vaishampayan UN, Heath EI, Hopkins AC, Cieslik MP, Wu Y-M, Robinson D, Baladandayuthapani V, Chinnaiyan AM, Alva AS. Clin Cancer Res, 2024 May 24; DOI:10.1158/1078-0432.CCR-24-0400
      PMID: 38787530
    • Journal Article
      MP57-14 THE IMMEDIATE EFFECTS OF PRIVATE EQUITY ACQUISITION OF UROLOGY PRACTICES ON THE MANAGEMENT OF NEWLY DIAGNOSED PROSTATE CANCER
      Faraj K, Kaufman S, Herrel L, Maganty A, Oerline M, Caram M, Shahinian V, Hollenbeck B. Journal of Urology, 2024 May; 211 (5S): e943 DOI:10.1097/01.ju.0001009420.83948.eb.14
    • Journal Article
      PD01-08 QUALITY OF TREATMENT WITH TARGETED THERAPIES FOR ADVANCED PROSTATE CANCER BY SPECIALIST: DO PATIENTS WHO ARE MANAGED BY UROLOGISTS FARE DIFFERENTLY?
      Faraj K, Oerline M, Kaufman S, Maganty A, Caram M, Shahinian V, Hollenbeck B. Journal of Urology, 2024 May; 211 (5S): e66 DOI:10.1097/01.ju.0001009540.33579.43.08